GSA Capital Partners LLP Takes $247,000 Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT)

GSA Capital Partners LLP acquired a new stake in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 48,165 shares of the company’s stock, valued at approximately $247,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. JTC Employer Solutions Trustee Ltd acquired a new stake in Adaptive Biotechnologies in the 3rd quarter valued at about $26,000. Ashton Thomas Securities LLC acquired a new stake in Adaptive Biotechnologies during the third quarter valued at approximately $34,000. Rothschild Investment LLC bought a new stake in Adaptive Biotechnologies during the second quarter worth approximately $36,000. MQS Management LLC acquired a new position in Adaptive Biotechnologies in the second quarter worth approximately $36,000. Finally, Nisa Investment Advisors LLC increased its holdings in shares of Adaptive Biotechnologies by 769.6% in the second quarter. Nisa Investment Advisors LLC now owns 13,392 shares of the company’s stock valued at $48,000 after buying an additional 11,852 shares in the last quarter. Institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Stock Up 7.3 %

Shares of Adaptive Biotechnologies stock opened at $4.69 on Friday. The stock has a market cap of $692.15 million, a PE ratio of -3.50 and a beta of 1.45. Adaptive Biotechnologies Co. has a 12 month low of $2.28 and a 12 month high of $6.70. The business has a fifty day simple moving average of $4.96 and a 200-day simple moving average of $4.30.

Analysts Set New Price Targets

ADPT has been the subject of several analyst reports. JPMorgan Chase & Co. upped their target price on Adaptive Biotechnologies from $5.00 to $6.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Piper Sandler upped their price objective on shares of Adaptive Biotechnologies from $6.00 to $7.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. Finally, BTIG Research lifted their target price on shares of Adaptive Biotechnologies from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, October 2nd.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.